Skip to main content
Top
Published in: Annals of Surgical Oncology 3/2018

01-12-2018 | ASO Author Reflections

ASO Author Reflections: 21-Gene Recurrence Scores in Male Breast Cancer

Authors: Ariella M. Altman, MD, Schelomo Marmor, PhD, MPH

Published in: Annals of Surgical Oncology | Special Issue 3/2018

Login to get access

Excerpt

Male breast cancer is an uncommon variant of breast cancer with an increasing incidence. Knowledge of breast cancer in men has traditionally been extrapolated from observations in women. Recent research focusing on male breast cancer has found increasing evidence that its pathophysiology may be unique compared with female breast cancer.1,2 Breast cancer in men is often diagnosed at a later age. The tumors are larger, show more nodal involvement, and are more likely to be estrogen receptor-positive (ER+)2, with different underlying genotypes.1 Furthermore, male breast cancer may have a lower 5-year survival rate.3 With the growing evidence that male breast cancer is unique, the role of the 21-gene recurrence scores (RS), commonly used to determine appropriate adjuvant treatment in ER+/human epidermal growth factor receptor 2-negative (HER2−) breast cancer in women, comes into question. Limited previous studies have evaluated the 21-gene recurrence scores for men with breast cancer.1,4
Literature
1.
go back to reference Massarweh SA, Sledge GW, Miller DP, McCullough D, Petkov VI, Shak S. Molecular characterization and mortality from breast cancer in men. J Clin Oncol. 2018;36:1396–404.CrossRefPubMedPubMedCentral Massarweh SA, Sledge GW, Miller DP, McCullough D, Petkov VI, Shak S. Molecular characterization and mortality from breast cancer in men. J Clin Oncol. 2018;36:1396–404.CrossRefPubMedPubMedCentral
3.
go back to reference Greif JM, Pezzi CM, Klimberg VS, Bailey L, Zuraek M. Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the National Cancer Data Base. Ann Surg Oncol. 2012;19:3199–204.CrossRefPubMed Greif JM, Pezzi CM, Klimberg VS, Bailey L, Zuraek M. Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the National Cancer Data Base. Ann Surg Oncol. 2012;19:3199–204.CrossRefPubMed
4.
go back to reference Grenader T, Yerushalmi R, Tokar M, et al. The 21-gene recurrence score assay (Oncotype DX™) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort. Oncology. 2014;87:1–6.CrossRefPubMed Grenader T, Yerushalmi R, Tokar M, et al. The 21-gene recurrence score assay (Oncotype DX™) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort. Oncology. 2014;87:1–6.CrossRefPubMed
5.
go back to reference Altman AM, Kizy S, Yuan J, et al. Distribution of 21-gene recurrence scores in male breast cancer in the United States. Ann Surg Oncol. 2018;25:2296–302.CrossRefPubMed Altman AM, Kizy S, Yuan J, et al. Distribution of 21-gene recurrence scores in male breast cancer in the United States. Ann Surg Oncol. 2018;25:2296–302.CrossRefPubMed
Metadata
Title
ASO Author Reflections: 21-Gene Recurrence Scores in Male Breast Cancer
Authors
Ariella M. Altman, MD
Schelomo Marmor, PhD, MPH
Publication date
01-12-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6951-2

Other articles of this Special Issue 3/2018

Annals of Surgical Oncology 3/2018 Go to the issue